These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16965395)

  • 61. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
    Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
    Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.
    Fong A; Garcia E; Gwynn L; Lisanti MP; Fazzari MJ; Li M
    Am J Clin Pathol; 2003 Jul; 120(1):93-100. PubMed ID: 12866378
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions.
    Sanchez-Fernandez de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Perez-Bacete M; Llombart-Bosch A
    Eur Urol; 1992; 21 Suppl 1():5-9. PubMed ID: 1425837
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion.
    McKenney JK; Gomez JA; Desai S; Lee MW; Amin MB
    Am J Surg Pathol; 2001 Mar; 25(3):356-62. PubMed ID: 11224606
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The pagetoid variant of bladder urothelial carcinoma in situ A clinicopathological study of 11 cases.
    Lopez-Beltran A; Luque RJ; Moreno A; Bollito E; Carmona E; Montironi R
    Virchows Arch; 2002 Aug; 441(2):148-53. PubMed ID: 12189504
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inverted variant of urothelial carcinoma of the urinary bladder: a report of three cases and a proposal for a new clinicopathologic entity.
    Terada T
    Int J Clin Exp Pathol; 2013; 6(4):766-70. PubMed ID: 23573325
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal growth factor receptors and blood group antigens.
    Limas C
    J Pathol; 1993 Sep; 171(1):39-47. PubMed ID: 8229455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
    Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder.
    Hashmi AA; Hussain ZF; Irfan M; Khan EY; Faridi N; Naqvi H; Khan A; Edhi MM
    BMC Urol; 2018 Jun; 18(1):59. PubMed ID: 29879970
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nerve hyperplasia: a unique feature of ketamine cystitis.
    Baker SC; Stahlschmidt J; Oxley J; Hinley J; Eardley I; Marsh F; Gillatt D; Fulford S; Southgate J
    Acta Neuropathol Commun; 2013 Oct; 1():64. PubMed ID: 24252413
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen.
    Ioachim E; Assimakopoulos D; Peschos D; Zissi A; Skevas A; Agnantis NJ
    Pathol Res Pract; 1999; 195(12):809-14. PubMed ID: 10631715
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa.
    Gunia S; Koch S; Hakenberg OW; May M; Kakies C; Erbersdobler A
    Am J Clin Pathol; 2011 Dec; 136(6):881-8. PubMed ID: 22095373
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
    Mallofré C; Castillo M; Morente V; Solé M
    Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
    Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
    Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Urinary bladder lesions after the Chernobyl accident: immunohistochemical assessment of p53, proliferating cell nuclear antigen, cyclin D1 and p21WAF1/Cip1.
    Romanenko A; Lee CC; Yamamoto S; Hori T; Wanibuchi H; Zaparin W; Vinnichenko W; Vozianov A; Fukushima S
    Jpn J Cancer Res; 1999 Feb; 90(2):144-53. PubMed ID: 10189884
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.